Compare FNKO & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNKO | ACOG |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 130.9M |
| IPO Year | 2017 | N/A |
| Metric | FNKO | ACOG |
|---|---|---|
| Price | $3.18 | $5.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.13 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.2M | 96.0K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $928,842,000.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.57 | $101.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $3.75 |
| 52 Week High | $14.65 | $11.54 |
| Indicator | FNKO | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 47.68 |
| Support Level | $2.72 | $5.66 |
| Resistance Level | $3.09 | $6.20 |
| Average True Range (ATR) | 0.24 | 0.47 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 32.96 | 69.59 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.